New combo drug trial targets Hard-to-Treat sarcomas
NCT ID NCT06308419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a combination of two drugs, gemcitabine and nab-sirolimus, in people with advanced leiomyosarcomas or soft-tissue sarcomas that have lost function in the TSC1 or TSC2 genes. The main goal is to find a safe and tolerable dose. The study plans to enroll 18 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine and nab-sirolimus
- What this could lead to
- If this works, it could point toward a new treatment option for people with advanced sarcomas that have specific genetic changes.
- What could go wrong
- This is a very early Phase 1 trial with only 18 people, focused on finding a safe dose. It is not yet known if the combination will shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Blood test may spot hidden sarcoma signals
- New pill may keep soft tissue sarcoma in check after chemo
- New drug takes aim at Hard-to-Treat sarcoma
- Dietary change explored as cancer support strategy